Today's journal articles

No journal articles today

Do you need further information on any of the agents being evaluated in the trial(s) below?  Let us know...

New Clinical Trials

No clinical trials today

Previous Journal Entries

Calcium-sensing receptor antagonist (calcilytic) NPS 2143 specifically blocks the increased secretion of endogenous Aβ42 prompted by exogenous fibrillary or soluble Aβ25-35 in human cortical astrocytes and neurons-Therapeutic relevance to Alzheimer's disease.

2D QSAR studies on Series of Human Beta - Secretase (BACE - 1) Inhibitors.

Overexpression of Hsp27 ameliorates symptoms of Alzheimer's disease in APP/PS1 mice.

Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease.

In vivo characterization of a bigenic fluorescent mouse model of Alzheimer's disease with neurodegeneration.

Dopamine Receptor D3 Expressed on CD4+ T Cells Favors Neurodegeneration of Dopaminergic Neurons during Parkinson's Disease.

A Highly Reproducible Model of Cerebral Ischemia/Reperfusion with Extended Survival in CB-17 Mice.

Reperfusion of cerebral artery thrombosis by the GPIb/vWF blockade with the nanobody ALX-0081 reduces brain infarct size in guinea pigs.

NDGA reduces secondary damage after spinal cord injury in rats via anti-inflammatory effects.

Neuroprotection with glatiramer acetate: evidence from the PreCISe trial.

Impact of P-glycoprotein and breast cancer resistance protein on the brain distribution of antiepileptic drugs in knockout mouse models.

The sonic hedgehog pathway mediates brain plasticity and subsequent functional recovery after bone marrow stromal cell treatment of stroke in mice.

Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson's disease.

Identification of a Small Molecule that induces ATG5-and-Cathepsin-L-Dependent Cell Death and modulates Polyglutamine Toxicity.

Increase ICAM-1 and LFA-1 expression by cerebrospinal fluid of subarachnoid hemorrhage patients: Involvement of TNF-α

Alzheimer's phenotypes induced by overexpression of human presenilin 2 mutant proteins stimulate significant changes in key factors of glucose metabolism.

MicroRNA - 144 Is Regulated by Activator Protein - 1 (AP - 1) and Decreases Expression of Alzheimer's Disease - related A Disintegrin And Metalloprotease 10 (ADAM10).

Overexpression of SIRT1 Protein in Neurons Protects against Experimental Autoimmune Encephalomyelitis through Activation of Multiple SIRT1 Targets.

G protein-coupled receptor kinase 2 and group I metabotropic glutamate receptors mediate inflammation-induced sensitization to excitotoxic neurodegeneration.

Changes in cognitive performance over a 1-year period in children and adolescents with multiple sclerosis.

Today's News Items

Merck Provides Update on Phase III Clinical Program for Preladenant, the Company’s Investigational Parkinson’s Disease Medicine

Training Courses & Meetings

No events listed

Previous News Items

XenoPort Reports Top-Line Results of Phase 3 Trial of Arbaclofen Placarbil for Spasticity in Multiple Sclerosis Patients

Upsher-Smith Successfully Completes Phase III Study of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Epilepsy in Patients with Refractory Partial-Onset Seizures

Biogen Idec Submits Application to FDA for Approval of PLEGRIDY™ (Peginterferon Beta-1a) in Multiple Sclerosis

Investigational New Drug Application Cleared by FDA for OMS824 in Huntington\'s Disease

Ceregene Reports Additional Efficacy Data From Parkinson\'s Disease Phase 2b Study

Cognoptix reaches halfway point of pre-pivotal clinical trial of drug/device test designed to identify Alzheimer\'s disease

---

For faster discovery, automatically organize PubMed results into categories